EchoIQ Ltd's stock surged 5.25% during intraday trading on Thursday following the announcement of a significant corporate development.
The company secured a definitive exclusive data licensing agreement with Advara HeartCare, providing EchoIQ with exclusive access to between 500,000 and 1 million de-identified echocardiography studies and associated clinical datasets. The agreement, which has an initial three-year term with an option to extend, is expected to provide valuable resources for the company's operations and development.